Model‐Based Once‐Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV‐1‐Infected Patients Aged ≥3 to

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|4|7|406-414

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.4, Iss.7, 2015-08, pp. : 406-414

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite

Darunavir/ritonavir − a POWERful option for HIV

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 622, 2011-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Ritonavir-boosted darunavir: a powerful option for treatment-experienced HIV-1-infected patients

By Menééndez-Arias Luis   Matamoros Tania   ÁÁlvarez Mar  

Future Virology, Vol. 3, Iss. 5, 2008-09 ,pp. : 423-434

Future Medicine

Access to resources Recommend Favorite

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

By Wills Todd   Vega Vivian  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 395-401

Informa Healthcare

Access to resources Recommend Favorite

Darunavir: In Treatment-Experienced Pediatric Patients with HIV-1 Infection

By McKeage Kate   Scott Lesley J.  

Pediatric Drugs, Vol. 12, Iss. 2, 2010-04 ,pp. : 123-131

Adis International

Access to resources Recommend Favorite